In vitro activity of biapenem and comparators against multidrug-resistant and carbapenem-resistant Acinetobacter baumannii isolated from tertiary care hospitals in Thailand
4
Issued Date
2019
Resource Type
Language
eng
Rights
Mahidol University
Rights Holder(s)
Faculty of Pharmacy Mahidol University
Suggested Citation
Jantana Houngsaitong, Preecha Montakantikul, Taniya Paiboonwong, Mullika T Chomnawang, Piyatip Khuntayaporn, Suvatna Chulavatnatol, จันทนา ห่วงสายทอง, ปรีชา มนทกานติกุล (2019). In vitro activity of biapenem and comparators against multidrug-resistant and carbapenem-resistant Acinetobacter baumannii isolated from tertiary care hospitals in Thailand. Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/50879
Title
In vitro activity of biapenem and comparators against multidrug-resistant and carbapenem-resistant Acinetobacter baumannii isolated from tertiary care hospitals in Thailand
Abstract
Acinetobacter baumannii is one of nosocomial pathogen which emerge as multidrugresistance
worldwide. Multidrug-resistant A. baumannii (MDRAB) and carbapenem-resistant
A. baumannii (CRAB) are highly concerned due to limitation of therapeutic options.
Antibacterial activity of biapenem was explored in order to overcome bacterial resistance. Total
of 412 A. baumannii clinical isolates from 13 tertiary care hospitals in Thailand were collected.
MIC values of biapenem and comparators; imipenem, meropenem, colistin, sulbactam,
ciprofloxacin ceftazidime and fosfomycin sodium, were determined by broth microdilution
method in accordance with the Clinical and Laboratory Standards Institute (CLSI) guidelines
(2016). In total, 320 isolates (77.67%) were MDRAB and 328 isolates (79.61%) were CRAB
and 58 were colistin-resistant AB (14.07%). A. baumannii showed widespread resistance to
ceftazidime, ciprofloxacin and carbapenems in more than 90% of the strains; resistance to
sulbactam, fosfomycin, and colistin were 85%, 60%, and 15% respectively. By comparison
among carbapenems, biapenem showed MIC50/90 of 16/32 which were at least 2-fold lower than
imipenem and meropenem (MIC50/90; 32/128, 32/64, respectively). In addition, 15% of
imipenem and meropenem-resistant A. baumannii were susceptible to biapenem. Also, 19% of
colistin-resistant A. baumannii were susceptible to biapenem. Biapenem showed a good activity
over other carbapenems against the MDRAB, CRAB and colistin-resistant AB strains. This
drug might be a therapeutic option as alone or combination for highly resistant bacteria.
Description
The 1st Pharmaceutical Sciences Asia Conference 2019 Theme : Pharmaceutical Sciences toward Health Innovation in the Disruptive Era. Bangkok Midtown Hotel, Thailand. August 22, 2019, page 37